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Summary
Objective: The aim of this study was to develop a specific immunoassay for PIIANP and measure its serum concentration in healthy controls
and in patients with osteoarthritis (OA) and rheumatoid arthritis (RA). In addition, we investigated circulating forms recognized by antiserum
IIA in pools of serum from healthy adults, patients with OA and patients with RA.
Design: Using as immunogen and standard the recombinant human Glutathione S-Transferase (GST)-exon 2 fusion protein of type II
collagen, we developed a competitive polyclonal antibody-based ELISA. We compare serum PIIANP levels in 43 patients with knee OA (23
women and 20 men; mean age: 62.6±9.6 yr), 63 women with RA (mean age: 54±16 yr) and 88 healthy controls (67 women, mean age:
53±13 yr and 21 men, mean age: 63±7 yr). We randomly selected serum in each group for analyze circulating forms.
Results: The immunoassay we developed demonstrated adequate intra and inter-assay precision (CV<10%) and dilution recovery (mean:
96%), allowing accurate measurements of serum PIIANP from 1.13 to 40 ng/ml. No significant cross-reactivity of the ELISA was observed
with purified intact human procollagen type I N-propeptide, circulating thrombospondin and von Willebrand factor, proteins which exhibit
significant sequence homology with PIIANP. Western blot analysis showed that antiserum IIA recognized two circulating immunoreactive
forms of approximately 80 and 100 KDa respectively in serum from healthy adults, patients with OA and RA but also in a pool of synovial
fluids from patients with OA.
Serum PIIANP levels were markedly decreased in patients with knee OA (12.0±3.2 vs 25.8±7.5 ng/ml for OA and controls respectively,
P<0.0001) and RA (14.1±2.5 ng/ml vs 21.7±7.6 ng/ml for RA and controls respectively, P<0.0001). In patients with RA, serum PIIANP levels
were higher in those taking low-dose prednisone compared to non-users (15.0±2.4 vs 13.5±2.4 ng/ml, P<0.05).
Conclusions: We have developed the first specific immunoassay for serum PIIANP which exhibits adequate technical performances. This
assay detects specifically two immunoreactive forms both in healthy adults and patients with arthritis and does not cross react with other
proteins with sequence homology with PIIANP. Levels of PIIANP were significantly decreased in patients with knee OA and RA suggesting
that type IIA collagen synthesis may be altered in these arthritic diseases. The measurement of type IIA collagen synthesis with this new
molecular marker may be useful for the clinical investigation of patients with joint diseases.
© 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Destruction and remodelling of articular cartilage are fea-
tures of both rheumatoid arthritis (RA) and osteoarthritis
(OA)1. However, in such diseases, catabolic processes are
combined with alterations in synthesis2–9. Thus, it is import-
ant to gain access to sensitive tools for assessing cartilage
synthesis, in addition to degradation markers.
In this aim, we focused on the synthesis of type II
collagen, the most abundant cartilage protein representing
80–95% of the total collagen content. Like fibril-forming
collagens I, III, V and XI, type II collagen is synthesized as
a procollagen form10. These procollagens are secreted
from the cell into the extracellular matrix where extension
propeptides (N-propeptide and C-propeptide) are removed
by specific proteinases before the mature molecules are
incorporated into fibrils in matrix10. Type II procollagen is
synthesized in two splice forms, type IIA and type IIB. Type
IIA contains an additional 207 base pair exon (exon 2)
encoding the 69 amino acid cysteine-rich domain of the
N-propeptide (Fig. 1).
Serum levels of these propeptides can thus be used as
specific markers of collagen synthesis and assays for type
I collagen N and C-propeptides have proven to be of
significant utility for the clinical investigation of metabolic
bone diseases including osteoporosis11.
*Address reprint requests to: J.C. Rousseau, INSERM Unit
403, Pavillon F, Hoˆpital E. Herriot, 69437 Lyon Cedex 03,
France. Tel: +33-4-72-11-74-31; Fax: +33-4-72-11-74-32; E-mail:
rousseau@lyon.inserm.fr
Received 7 July 2003; revision accepted 3 February 2004.
International
Cartilage
Repair
Society
OsteoArthritis and Cartilage (2004) 12, 440–447
© 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2004.02.004
440
Currently, only assays for the C-propeptide of type II
procollagen (PIICP also referred to as chondrocalcin or
pCOL-IIC or CPII) have been described to assess type II
collagen synthesis12,13. Serum PIICP levels have been
shown to be increased in patients with RA compared to
controls whereas patients with OA exhibited decreased
levels14. However, there was no data concerning the
measurement of the N-propeptide in body fluids in spite
of major advances in the knowledge of the IIA form
expression that have been achieved in the last few years.
This long form was known to be synthesized mainly by
skeletal progenitor cells and non cartilaginous embryonic
tissues15–17 but also by a distinct population of cells in
osteophytes18 and chondrocytes in the fracture callus19
while the IIB form was know to be mainly expressed in adult
cartilage15.
Recently, type IIA procollagen was shown to be re-
expressed by adult articular chondrocytes in OA cartilage,
suggesting the potential reversion of the cells to a chondro-
progenitor cellular phenotype in this disease20. Alterna-
tively, type IIA procollagen and type X collagen were shown
to be expressed by chondrocytes in the upper zone of
moderately and severely affected human OA cartilage
suggesting that articular chondrocytes undergo hyper-
trophic changes in osteoarthritis cartilage21. Taken to-
gether, these results suggested that IIA form of type
II collagen play an important but not clearly established role
in the pathogenesis of osteoarthritis.
We anticipated that the propeptide of type IIA procolla-
gen (PIIANP), arising from the maturation of type IIA
procollagen, could be found in serum and be used as a
specific marker of type IIA procollagen synthesis in articular
diseases.
The aim of this study was to develop an immunoassay for
PIIANP and investigate serum PIIANP levels in healthy
adults and patients with OA or RA and characterize circu-
lating forms recognized by antiserum IIA.
Methods
HEALTHY SUBJECTS
Healthy subjects included 67 women (mean age:
53±13 yr) and 21 men (mean age: 63±7 yr). Healthy
women and men were randomly selected from two large
population-based cohorts involved in prospective studies
on the determinants of bone loss in women (OFELY study,
1039 female volunteers, 31–89 yr of age)22 and men
(MINOS study, 842 healthy male volunteers, 50–85 yr of
age)23. All healthy subjects came from the same region of
France as the patients with knee OA and RA. None of the
control subjects had evidence of OA assessed by clinical
examination, questionnaire and X-ray films of the thoracic
and lumbar spine and were without disease or treatment
that could interfere with bone metabolism including hor-
mone replacement therapy in postmenopausal women.
PATIENTS WITH KNEE OSTEOARTHRITIS
The study group included 43 outpatients suffering from
knee OA (23 women and 20 men; mean age: 62.6±9.6 yr).
They consulted in the department of Rheumatology of the
Centre Hospitalier Lyon Sud (Lyon, France). All patients
fulfilled the American College of Rheumatology criteria for
primary knee OA24. All patients had chronic daily pain of
the knee for at least 3 months (median: 10 yr) and radio-
graphic evidence of OA with joint space narrowing (JSN)
when using the posteroanterior view of the knees flexed at
30° (schuss view). Patients presenting an advanced stage
of OA with a minimum joint space width (JSW) lesser than
1 mm were excluded. All women were postmenopausal and
all patients were without treatment that could interfere with
bone metabolism including estrogen replacement therapy,
dilantin, thyroid replacement therapy and diuretics. Pain
and physical function were assessed by the Western
Ontario and McMaster Universities multifunctional
(WOMAC)25 index, using a visual analogue scale as a
grading system. A subset of 53 healthy age and sex-
matched subjects (32 women and 21 men, mean age:
62.4±7.7 yr) was used as controls for patients with knee
OA.
PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
Sixty three women suffering from RA were studied (mean
age: 54±16 yr; median disease duration: 6 yr). All patients
fulfilled the American College of Rheumatology criteria for
RA disease revised in 198726. Twenty four were on low-
dose corticosteroids (<10 mg/day prednisone). Patients
with renal insufficiency were excluded. A subset of 67
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Fig. 1. Schematic representation of type IIA/IIB procollagen. Type II collagen is expressed in two forms of IIA and IIB, as the result of
alternative splicing of exon 2 in NH2-propeptide region. Polyclonal antibody IIA raised against the protein part encoded by exon 2 recognizes
specifically IIA N-propeptide.
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healthy age-matched women (mean age: 53±13 yr) was
used as controls for patients with RA.
COLLECTION AND PROCESSING OF BLOOD AND SYNOVIAL FLUID
SAMPLES
In all healthy adults, patients with knee OA and patients
with RA, blood samples were collected fasting in the
morning before 10 am. After centrifugation at 1000 g for
10 min, serum were stored at −70°C until used. Synovial
fluids were collected in sterile tubes and stored at −20°C.
Before used, synovial fluids were centrifuged at 15 000 g
for 10 min to remove all cells and debris.
RECOMBINANT PROTEIN AND SPECIFIC ANTIBODIES
Recombinant fusion protein GST-exon 2 and polyclonal
antibody anti-IIA were obtained from Dr. L. Sandell labora-
tory (St Louis, MO) and have previously been described20.
The specificity of polyclonal antibody IIA was demonstrated
by Western blot against recombinant protein (prior and
after cleavage with thrombin) and against IIA procollagen
from medium culture of day 54 human fetal ribs27.
ELISA FOR PIIANP
Maxisorp microtiter plates (Nunc, Roskilde, Denmark)
were used throughout the study. Each well was coated
overnight, without shaking, at +4°C with 100 µl of recom-
binant fusion protein GST-exon 2 (10 ng/ml) in PBS. After
coating, wells were saturated 2 h at room temperature with
200 µl of PBS, BSA 1% (Sigma, St Louis, MO) on a
microwell plate rotation apparatus (40 rpm). Microwells
were washed with 200 µl of PBS, 1% BSA, 0.05% Tween
(four times between each step of the protocol). After
washing, 100 µl of standards (recombinant fusion protein
GST-exon 2: 0 (PBS/BSA/Tween), 2.5, 5, 7.5, 10, 15, 20,
30, 40 ng/ml) or serum (samples and controls) were incu-
bated with shaking 4 h at room temperature with 100 µl/well
of IIA antiserum (1/1650 final). Serum must be centrifuged
15 min at +4°C (14 000 g) before used. After washing, the
peroxidase conjugated anti-rabbit (diluted: 1/8000, Sigma,
St Louis, MO) was added (100 µl/well) and incubated at
room temperature for 1 h with shaking. After washing,
100 µl H2O2/Tetramethylbenzidine substrate-indicator
solution (Sigma, St Louis, MO; 1 tablet in 10 ml of 0.05 M
phosphate-citrate buffer, pH=5 with 2 µl H2O2) was added
to each well. After incubation at room temperature for
30 min with shaking, the colour reaction was stopped by
addition of 100 µl 2M H2SO4/well and the optical density
was read at 450 nm in a Dynatech MR 7000. Each sample
was run in duplicate.
PURIFICATION OF INTACT PROCOLLAGEN TYPE I N-PROPEPTIDE
(PINP)
The intact in-vivo-cleaved PINP was purified from human
ascitic fluids as described previously28. The purity of PINP
was confirmed by SDS-polyacrylamide gel electrophoresis
and amino acid sequencing after amino-terminal deblock-
ing. Amino terminal pyroglutamate residues were removed
essentially as described by Podell and Abraham29.
GST-EXON 2 AFFINITY CHROMATOGRAPHY
Recombinant GST-exon 2 protein (0.5 mg) was coupled
on a HiTrap NHS-activated HP column (1 ml, Amersham
Pharmacia) in 0.2 M NaHCO3, 0.5 M NaCl pH 8.3 for
30 min at room temperature (coupling efficiency: 89%).
After washing out the non-specifically bound ligands and
deactivation of any excess active groups, antiserum IIA
(40 µl diluted in 1 ml 20 mM sodium phosphate pH 7) was
applied to the column for 5 h at room temperature. Un-
bound material was retrieved and the column was washed
with 1 ml 20 mM sodium phosphate. Specific antibodies
were eluted with 0.1 M glycine pH 2.7 with 1 M Tris added
in the collected fractions containing IgG.
CHARACTERIZATION OF CIRCULATING IMMUNOREACTIVE FORMS
RECOGNIZED BY ANTISERUM AGAINST IIA
Pools of randomly selected serum from 10 healthy
donors, 10 patients with OA and 10 patients with RA and
a pool of randomly selected synovial fluids of 10 knee
osteoarthritis patients were diluted 10 times in PBS. Serum
and synovial fluid pools were boiled 5 min and resolved
(15 µl/well) in a 5% Tris/Tricine gel under reducing con-
ditions. After transfer to a nitrocellulose membrane over-
night at 30 V in 15 mM Tris, 120 mM Glycine, pH 8.3,
containing 20% methanol, membranes were blocked with
5% non fat milk in PBS with shaking. The following anti-
bodies were applied at the appropriate dilution in PBS with
1% non fat milk overnight at +4°C with shaking: IIA anti-
serum and unbound material after GST-exon 2 affinity
chromatography at 1/1000; non immune serum at 1/400;
anti-von Willebrand factor (Dako, Carpinteria, CA) at 1/400
and anti-thrombospondin (NeoMarkers, Fremont, CA) at
1/400. After washing, membranes were incubated with
anti-rabbit (Jackson ImmunoResearch) peroxidase con-
jugate in PBS, 1% non fat milk for one hour at room
temperature with shaking. After further washing, antibody
binding was detected using Western Lightning Chemilumi-
nescent Reagent kit (PerkinElmer, Boston, MA).
STATISTICAL ANALYSIS
Comparison of serum PIIANP levels between healthy
controls and patients with OA or RA was assessed by the
non-parametric Mann–Whitney U test. The correlation
between PIIANP and age was assessed by Spearman rank
correlation.
Results
ANALYTICAL PERFORMANCES OF THE PIIANP ELISA
Using as immunogen and standard the recombinant
fusion protein GST-exon 2, we developed a competitive
polyclonal antibody-based ELISA and a typical standard
curve is shown on Fig. 2. Intra and inter-assay precisions
were under 10% (Table IA). Mean dilution recovery and
mean spiking recovery were 96% and 128% respectively
(Table IB and Table IC). The detection limit defined as the
concentration 2SDs above that of the lowest calibrator was
1.1 ng/ml. We found no significant cross-reactivity of this
assay with purified intact human PINP (data not shown).
The stability of serum PIIANP was tested over three freeze-
thaw cycles (Table ID). After 2 cycles, no changes of serum
PIIANP concentrations were noted. However at the third
cycles, serum PIIANP decreased by a mean of 26%.
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CHARACTERIZATION OF CIRCULATING IMMUNOREACTIVE FORMS
RECOGNIZED BY ANTISERUM AGAINST IIA
Western blot analysis showed that IIA antiserum recog-
nizes two immunoreactive bands with molecular weights of
80–100 KDa in the serum of healthy adults, patients with
OA and patients with RA (Fig. 3, lanes 1,2,3). Analysis of
synovial fluids from patients with knee OA showed the
same two bands which were detected in serum (Fig. 3, lane
4). The specificity of antibody binding was verified by
preabsorbing antiserum IIA with recombinant GST-exon
2 protein (affinity column) which resulted in the loss of
immunoreactivity (Fig. 3, lanes 5,6,7,8). We then verified
that these 2 bands were not recognized by anti-
thrombospondin and anti-von Willebrand factor antibodies
(Fig. 3, lanes 9,10) and additionally that antiserum IIA did
not recognize bands corresponding to thrombospondin and
von Willebrand factor (Fig. 3, compare lanes 1,2,3,4 with
lanes 9,10). As negative control, a non-immune serum
showed no cross-reactivity with the two bands recognized
specifically by IIA antiserum (Fig. 3, lane 11).
AGE-RELATED CHANGES OF SERUM PIIANP IN HEALTHY ADULTS
(TABLE II)
Serum PIIANP levels were measured in 88 healthy
subjects including 21 men (mean age: 63±7 yr), 29
pre-menopausal women (mean age: 39±4 yrs) and 38
post-menopausal women (mean age: 63±7 yrs). Serum
PIIANP increased significantly with age in women (r=0.63;
P<0.001) with a significant difference between pre and post
menopausal women (P<0.001). We found no significant
difference in serum PIIANP between age-matched men
and women (P=0.17).
CONCENTRATIONS OF SERUM PIIANP IN PATIENTS WITH KNEE OA
AND PATIENTS WITH RA
The mean serum concentration of PIIANP was signifi-
cantly decreased (P<0.0001) in patients with knee OA
(12.0±3.2 ng/ml vs 25.8±7.5 ng/ml, Fig. 4a) and RA
(14.1±2.5 ng/ml vs 21.7±7.6 ng/ml, Fig. 4b) compared to
sex and age-matched healthy controls. When using the
mean – 1 SD of the controls as the lower limit of the normal
range, 97% and 57% of patients with knee OA and RA
respectively, had serum levels below that limit. The distri-
bution of PIIANP serum levels was more narrow in patients
with OA or RA than in healthy controls (Fig. 4a and b).
In patients with RA treated with low-dose corticosteroids,
serum PIIANP was slightly but significantly higher than in
untreated patients (15.0±2.4 vs 13.5±2.4 mg/ml, P<0.05).
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Fig. 2. Standard curve produced by duplicate measurements of the mean optical density at 450 nm of 9 PIIANP
standards.
Table IA
Intra and inter-assay precisions
Sample Serum PIIANP (ng/ml) CV (%)
Intra-assay variability was tested by measuring 3 samples 10 times
in the same run
A 9.6 7.4
B 12.8 8.5
C 25.4 9.0
Inter-assay variability was tested by measuring 3 samples in
duplicate in 5 different runs
Sample Serum PIIANP (ng/ml) CV (%)
D 9.0 8.6
E 27.0 6.0
F 36.3 1.5
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Discussion
In that study, we developed for the first time an immu-
noassay for serum PIIANP and investigated its value to
detect abnormalities of systemic type IIA collagen synthesis
in patients with OA or RA. The present study showed that
the PIIANP ELISA demonstrated adequate technical per-
formances with respect to precision (intra and inter assay
variation <10%), dilution of serum samples and specificity,
suggesting that this assay allows accurate measurement of
serum PIIANP levels.
The region encoded by exon 2, specific of the IIA form of
the N-propeptide of type II collagen, is absent in the IIB
form. It has the highest sequence homology (68%) with the
interstitial collagen chains 1(I), but also present significant
homologies with the extracellular matrix proteins throm-
bospondin 1 and 2 and von Willebrand factor C domain27.
Consequently, we analyzed the specificity of the PIIANP
polyclonal antibody with these circulating proteins.
We found no significant cross-reactivity of the PIIANP
antiserum with purified intact human N-propeptide of type I
collagen (PINP) composed of two pro-1(I) chains and one
pro-2(I) chain, in agreement with previously reported
findings27 and with circulating thrombospondin and von
Willebrand factor. Thus, these data suggest that indeed the
ELISA we have developed is specific for circulating PIIANP.
In Western blot, circulating PIIANP was present in at
least two immunoreactive forms with molecular weights of
about 80 and 100 KDa respectively, in serum from healthy
adults and patients with RA but also in serum and synovial
fluid from patients with OA. Antiserum IIA pre-incubated
with recombinant GST-exon 2 protein did not anymore
recognize these two bands indicating that these circulating
immunoreactive forms are indeed related to PIIANP. The
molecular weights of these two circulating forms are how-
ever higher than the estimated molecular weight of the
Table IB
Dilution recovery. Samples with high levels were serially diluted with ELISA buffer
Sample Dilution Serum PIIANP expected (ng/ml) Serum PIIANP measured (ng/ml) Recovery (%)
G Undiluted – 25.9 –
80% 20.7 21.1 102
60% 15.5 13.3 86
40% 10.3 9.5 92
H Undiluted – 24.2 –
80% 19.3 14.0 72
60% 14.5 13.9 96
40% 9.7 12.4 128
I Undiluted – 30.4 –
80% 24.3 23.2 95
60% 18.2 17.8 98
40% 12.2 12.1 99
Table IC
Spiking recovery. Known quantities of recombinant GST-exon 2 protein (50 µl) were added to human serum (50 µl)
Sample Standard PIIANP expected (ng/ml) PIIANP measured (ng/ml) Recovery%
J Undiluted – 25.8 –
+5 ng/ml 15.4 16.8 109
+10 ng/ml 17.9 22.8 127
K Undiluted – 14.3 –
+2.5 ng/ml 8.4 10.3 123
+10 ng/ml 12.1 19.8 164
L Undiluted – 10.6 –
+5 ng/ml 7.8 8.5 109
+10 ng/ml 10.3 14.1 137
Table ID
Stability of serum PIIANP. Samples were tested after 1, 2 and 3
freeze/thaw cycles
Sample freeze/thaw cycle Serum PIIANP (ng/ml)
M 1 20.2
2 23.4
3 14.5
N 1 26.9
2 28.3
3 20.8
O 1 32.5
2 30.5
3 24.7
Fig. 3. Western blot analysis. Pools of randomly selected serum
from healthy donors (lanes 1,5,9,10,11), patients with OA (lanes
2,6), patients with RA (lanes 3,7) and a pool of randomly selected
synovial fluids of knee osteoarthritis patients (lanes 4,8) were
probed with the following antibodies: anti-IIA (lanes 1,2,3,4), anti-
IIA pre-absorbed with PIIANP (lanes 5,6,7,8), anti-von Willebrand
factor (lane 9), anti-thrombospondin (lane 10) or non-immune
serum (lane 11).
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monomeric N-propeptide IIA, i.e. 15–20 KDa. It is unlikely
that these two forms correspond to PIIANP bound to
unknown serum proteins because the experiments were
performed under reducing conditions on boiled samples, a
procedure which would have disrupted these aggregates.
Alternatively, these large molecular forms could be the
trimeric N-propeptide IIA or multiple propeptides which
include triple helical regions bound each other in the
N-telopeptide region by cross-linking molecules such
as pyridinoline30, although further experiments will be
necessary to confirm that hypothesis.
The significant levels of PIIANP measured in the serum
of controls may be surprising because it is believed that
type IIA collagen is predominantly expressed in embryonic
and not mature normal tissues15–17. Although immuno-
histochemistry studies were unable to detect type IIA
procollagen in mature cartilage of healthy controls even
after extensive protease treatments20, animal studies
showed however mRNA expression of type IIA procollagen
in culture of adult bovine chondrocytes31 and in articular
cartilage of healthy dogs32 and mice33. In addition, detect-
able concentrations of type IIA procollagen protein were
shown in the pellets of adult bovine chondrocytes34. Apart
from articular cartilage, type IIA may arise in part from other
body areas such as adult vitreous or intervertebral disc
tissues35–37. It remains however unclear whether these
non-articular cartilage tissues continue to synthesize type
IIA in adults. Additional studies are needed to elucidate the
relative contribution of articular cartilage and others tissues
to the global serum levels of PIIANP.
In OA patients, we found decreased levels of serum
PIIANP compared to controls which is in apparent contra-
diction with the observed reexpression of type IIA collagen
by adult articular chondrocytes in OA cartilage20. One of
the reasons for this discrepancy could be related to the fact
that serum PIIANP levels in OA may reflect systemic
alterations of type IIA collagen metabolism which may not
be related to abnormalities of cartilage metabolism of the
signal joint. This hypothesis has also been suggested to
explain the decreased serum PIICP levels observed in
patients with OA14, which is likely to reflect synthesis of
both IIA and IIB collagens. The clinical significance of
decreased serum PIIANP and PIICP in OA should be
interpreted with caution. Indeed, measurement of PIICP in
cartilage tissue extract14 and synovial fluid6 were shown to
be increased in patients with knee OA compared to healthy
controls. However, these increased levels are mainly found
in early and mid stages of the disease, and with advancing
OA, synovial fluid levels of PIICP progressively decrease
probably due to decreased cartilage mass and chondro-
cytes end stage failure. In our study, we only analyzed
serum and thus it remains to be determined whether the
conflicting data between synovial fluid and serum PIICP
levels will also apply to PIIANP. Nevertheless the findings
of our present study are likely to be of clinical relevance for
the investigation of patients with OA. Indeed, we recently
confirmed decreased serum PIIANP levels in another inde-
pendent population of patients with knee OA, and lower
levels were associated with a more rapid progression of
cartilage damage assessed prospectively over one year by
either radiography or chondroscopy of the signal knee38.
Our study showed that serum PIIANP levels are also
markedly decreased in RA patients compared to controls.
Conversely, levels of serum PIICP were found to be in-
creased in serum14 without significant differences between
aggressive and non-aggressive disease13. The reasons of
this discrepancy between serum levels of PIIANP and
PIICP in patients with RA is unclear, but may result from
differences in populations characteristics, our patients be-
ing characterized by a long standing disease. Alternatively,
these differences may also result from the fact that PIICP
reflects the synthesis of both IIA and IIB procollagen
molecules whose regulation may differ in RA. It seems
unlikely that the decrease of PIIANP in RA was the result of
increased proteinase degradation of propeptide at the
tissue level. Indeed, Fukui30 showed recently that the
Table II
Serum PIIANP levels in healthy men and women
Men (N=21) Pre-menopausal women (N=29) Post-menopausal women (N=38)
Age (yrs) 63±7 39±4 63±7
Mean±SD (ng/ml) 27.7±7 17.6±5 24.8±7
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Fig. 4. Box plots distribution of serum PIIANP levels in healthy
controls and in patients with OA (A) or RA (B). From the bottom up,
the box indicates the 25th, 50th (median) and 75th percentiles,
while the bars indicate the 10th and 90th percentiles respectively.
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antibody raised against IIA which was used in this study still
recognizes recombinant N-propeptide IIA even after cleav-
age by the different MMPs know to be involved in the
destruction of articular cartilage.
Decreased PIIANP levels in RA are more likely to reflect
in part the inhibitory effects of inflammatory cytokines such
as interleukin-1 and tumour necrosis factor- on type II
collagen synthesis39–41. In support of this hypothesis, we
found that patients treated with steroids, which are potent
anti-inflammatory agents, are characterized by higher
serum PIIANP levels compared to non-users. Thus serum
PIIANP could potentially be a useful marker to investigate
the effects of drugs aimed at increasing the capacity of
cartilage repair.
In summary, we have developed the first ELISA for
serum procollagen type IIA N-propeptide and characterized
its circulating immunoreactive forms in humans. Serum
PIIANP levels were decreased in patients with OA or RA
suggesting that this new molecular marker may be useful to
investigate the alterations of cartilage metabolism probably
in combination with markers of type II collagen degradation
as recently reported38 and also to monitor efficacy of
disease modifying therapy, especially anabolic treatments.
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